BlossomHill Therapeutics, Inc. (BLSM) vs Puma Biotechnology, Inc. (PBYI)
A side-by-side comparison of BlossomHill Therapeutics, Inc. and Puma Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BLSM
BlossomHill Therapeutics, Inc.
$17.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PBYI
Puma Biotechnology, Inc.
$9.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BLSM vs PBYI
growth of $100 · dividends reinvested · last 1yBLSM +24.6% (+24.6%/yr)PBYI +25.7% (+25.7%/yr)PBYI compounded faster over this window
BLSM PBYI
BLSM vs PBYI: by the numbers
- •BLSM is the larger company ($503M vs $484M market cap).
- •PBYI is profitable (11.55% net margin) while BLSM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | BLSM | PBYI |
|---|---|---|
| P/E ratio | N/A | 18.40 |
| Forward P/E | N/A | 25.00 |
| P/S ratio | N/A | 2.09 |
| P/B ratio | N/A | 3.49 |
| EV / EBITDA | N/A | 10.41 |
| FCF yield | N/A | 8.50% |
Profitability
| Metric | BLSM | PBYI |
|---|---|---|
| Gross margin | 0.00% | 74.83% |
| Operating margin | 0.00% | 13.16% |
| Net margin | 0.00% | 11.55% |
| ROE | N/A | 19.28% |
| ROIC | -43.41% | 18.26% |
Growth (annualized)
| Metric | BLSM | PBYI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 0.29% |
| FCF CAGR (5Y) | N/A | 90.51% |
| Total return CAGR (5Y) | N/A | 9.26% |
Frequently asked
- Is BLSM or PBYI more profitable?
- PBYI runs the higher net margin — BLSM at 0.00% versus PBYI at 11.55%.
Go deeper
Dig into the metrics
Puma Biotechnology P/E ratioBlossomHill Therapeutics ROEPuma Biotechnology ROEBlossomHill Therapeutics operating marginPuma Biotechnology operating marginBlossomHill Therapeutics revenue growthPuma Biotechnology revenue growthBlossomHill Therapeutics free cash flowPuma Biotechnology free cash flow
BlossomHill Therapeutics & Puma Biotechnology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.